Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Individual Expanded Access Protocol for the Emergency Use of REGN3470-3471-3479 in a Patient With Confirmed Ebola Virus Disease (EVD) or an Individual With a High-risk Exposure to Zaire Ebolavirus (EBOV)

Trial Profile

Individual Expanded Access Protocol for the Emergency Use of REGN3470-3471-3479 in a Patient With Confirmed Ebola Virus Disease (EVD) or an Individual With a High-risk Exposure to Zaire Ebolavirus (EBOV)

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 10 Jul 2018

At a glance

  • Drugs REGN 3470/3471/3479 (Primary)
  • Indications Ebola virus infections
  • Focus Expanded access; Therapeutic Use
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 10 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top